Login to Your Account



EUSA's Erwinaze Approval Positions Private Co. for Exit

By Trista Morrison
Staff Writer

Monday, November 21, 2011
EUSA Pharma Inc.'s FDA approval of acute lymphoblastic leukemia (ALL) drug Erwinaze (asparaginase Erwinia chrysanthemi) means the privately held specialty pharma firm may now be poised for an exit.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription